Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease (P12-3.006)

To identify obstacles, solutions, and treatment recommendations for initiating therapy with monoclonal antibodies (mAbs) for Alzheimer’s disease (AD) that have been highlighted in published literature.

Authors

Jeffrey Gelblum
David Weisman (ORCID: https://orcid.org/0000-0001-5082-8955)
Katie Yoest

Institutions

MedCom (DE)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000211823
Primary Topic: Computational Drug Discovery Methods
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease (P12-3.006)

Jeffrey Gelblum, David Weisman, Katie Yoest

Apr 7, 2025

Neurology

Computational Drug Discovery Methods

article

Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease (P12-3.006)

Jeffrey Gelblum, David Weisman, Katie Yoest

April 7, 2025article en

Abstract

NeurologyVol. 104(7_Supplement_1)

MedCom (DE)

Openalex Percentile: Top 92%

Computational Drug Discovery Methods

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease (P12-3.006) — Jeffrey Gelblum, David Weisman, et al. · Neurology (2025) | TGRS Research Map | TGRS